Psych CASC / OSCE · Psychopharmacology — SSRIs
Starting an SSRI with black-box counselling (CASC)
CASC-style station: collaborative consent for SSRI start, accurate black-box explanation, sexual side-effect and discontinuation counselling, safety plan, without coercion or false reassurance.
On this page
Study tools
Target exams
Station instructions (candidate)
You have 7 minutes. Engage the patient and parent. Validate fears about suicide risk and addiction language online. Explain accurately that SSRIs are not addictive in the substance-use sense but can cause discontinuation symptoms if stopped abruptly, and that a black-box warning means closer early monitoring because a minority of young people experience increased suicidal thoughts after starting — while untreated depression also carries suicide risk.[1][2][5] Offer a collaborative plan: optional sertraline start low, early review, safety plan, sexual side-effect discussion, and psychological therapy pathway. Do not coerce. Do not claim zero risk. Do not dismiss the parent.
References7ShowHide
- [1]Hammad TA, Laughren T, Racoosin J Suicidality in pediatric patients treated with antidepressant drugs Arch Gen Psychiatry, 2006.PMID 16520440
- [2]Stone M, Laughren T, Jones ML, et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration BMJ, 2009.PMID 19671933
- [3]Malhi GS, Bell E, Bassett D, et al. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders Aust N Z J Psychiatry, 2021.PMID 33353391
- [4]Montejo AL, Llorca G, Izquierdo JA, et al. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients J Clin Psychiatry, 2001.PMID 11229449
- [5]Schatzberg AF, Blier P, Delgado PL, et al. Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research J Clin Psychiatry, 2006.PMID 16683860
- [6]Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis Lancet, 2018.PMID 29477251
- [7]March J, Silva S, Petrycki S, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial JAMA, 2004.PMID 15315995